Search Results

Treatment of locally advanced and metastatic basosquamous carcinoma, navigating among sonic hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapy, and radiotherapy: A case series and literature review.

• Authors : Zelin E; Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.; Mazzoletti V

Subjects: Carcinoma, Basal Cell*/Carcinoma, Basal Cell*/Carcinoma, Basal Cell*/drug therapy ; Carcinoma, Basal Cell*/Carcinoma, Basal Cell*/Carcinoma, Basal Cell*/radiotherapy ; Skin Neoplasms*/Skin Neoplasms*/Skin Neoplasms*/drug therapy

• Source: The Australasian journal of dermatology [Australas J Dermatol] 2024 Mar; Vol. 65 (2), pp. 103-113. Date of Electronic Publication: 2023 Nov 05.Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 0135232 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

免疫检查点抑制剂相关肾上腺损伤病例分析.

• Authors : 徐文东¹ ; 陶静怡²; 李菁³

• Source: Journal of Changzhou University (Natural Science Edition) / Changzhou Daxue Xuebao (Ziran Kexue Ban). Nov2024, Vol. 36 Issue 6, p90-97. 8p.

Record details

Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy.

• Authors : Ntwasa M; Department of Life and Consumer Sciences, University of South Africa, Cnr Pioneer Road and Christiaan de Wet Road, Florida, Johannesburg 1710, South Africa.

Subjects: Proto-Oncogene Proteins c-mdm2*/Proto-Oncogene Proteins c-mdm2*/Proto-Oncogene Proteins c-mdm2*/metabolism ; Proto-Oncogene Proteins c-mdm2*/Proto-Oncogene Proteins c-mdm2*/Proto-Oncogene Proteins c-mdm2*/antagonists & inhibitors ; Immunotherapy*/Immunotherapy*/Immunotherapy*/methods

• Source: Cells [Cells] 2024 Jun 29; Vol. 13 (13). Date of Electronic Publication: 2024 Jun 29.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

Record details

Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.

• Authors : Tan Z; Department of Interventional Radiology, The Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, Jiangsu, China.; Zhang J

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/pathology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/pathology

• Source: PloS one [PLoS One] 2023 Oct 16; Vol. 18 (10), pp. e0290644. Date of Electronic Publication: 2023 Oct 16 (Print Publication: 2023).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review.

• Authors : Gong, Hongyu (AUTHOR); Ong, Siew Chin (AUTHOR); Li, Fan (AUTHOR)

Subjects: IMMUNE checkpoint inhibitors; HEPATOCELLULAR carcinoma; COST effectiveness

• Source: Health Economics Review. 7/5/2024, Vol. 14 Issue 1, p1-16. 16p.

Record details

Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors.

• Authors : Bestion E; Genoscience Pharma, 13006 Marseille, France.; Raymond E

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Liver Neoplasms*; Humans

• Source: Cells [Cells] 2023 Jun 23; Vol. 12 (13). Date of Electronic Publication: 2023 Jun 23.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

Record details

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).

• Authors : Uematsu S; Department of Respiratory Medicine, Osaka Red Cross Hospital, Osaka, Japan.; Kitazono S

Subjects: Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/chemically induced ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy

• Source: Thoracic cancer [Thorac Cancer] 2023 Jan; Vol. 14 (2), pp. 168-176. Date of Electronic Publication: 2022 Nov 21.Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet

Record details

A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner.

• Authors : El-Sayes N; McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.; Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 4K1, Canada.

Subjects: Oncolytic Virotherapy*; Adenocarcinoma/Adenocarcinoma/Adenocarcinoma/*therapy ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use

• Source: International journal of molecular sciences [Int J Mol Sci] 2022 Feb 03; Vol. 23 (3). Date of Electronic Publication: 2022 Feb 03.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details

Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma.

• Authors : Morante M; Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria, 39011 Santander, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28009 Madrid, Spain.

Subjects: Melanoma*/Melanoma*/Melanoma*/pathology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology; Humans

• Source: Biomolecules [Biomolecules] 2022 Oct 26; Vol. 12 (11). Date of Electronic Publication: 2022 Oct 26.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X

Record details

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

• Authors : Wu Q; School of Medical Imaging, Hangzhou Medical College, Hangzhou, 310053, Zhejiang, China.; Qian W

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Biological Products*/Biological Products*/Biological Products*/therapeutic use

• Source: Journal of hematology & oncology [J Hematol Oncol] 2022 Oct 08; Vol. 15 (1), pp. 143. Date of Electronic Publication: 2022 Oct 08.Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722

Record details